vs
Side-by-side financial comparison of CoastalSouth Bancshares, Inc. (COSO) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $21.3M, roughly 1.8× CoastalSouth Bancshares, Inc.). CoastalSouth Bancshares, Inc. runs the higher net margin — 31.7% vs -161.8%, a 193.5% gap on every dollar of revenue. CoastalSouth Bancshares, Inc. produced more free cash flow last quarter ($-5.9M vs $-71.3M).
CoastalSouth Bancshares, Inc. is a U.S.-based regional bank holding company. It provides a full range of personal and commercial banking services including deposit accounts, consumer loans, mortgages, commercial financing and wealth management solutions for retail customers and small-to-medium enterprises across the U.S. Gulf Coast region.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
COSO vs IBRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $38.3M |
| Net Profit | $6.7M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 41.2% | -169.0% |
| Net Margin | 31.7% | -161.8% |
| Revenue YoY | — | 407.0% |
| Net Profit YoY | — | -4.7% |
| EPS (diluted) | $0.54 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $38.3M | ||
| Q3 25 | $21.3M | $32.1M | ||
| Q2 25 | $19.9M | $26.4M | ||
| Q1 25 | — | $16.5M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $6.1M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $6.7M | $-67.3M | ||
| Q2 25 | $6.0M | $-92.6M | ||
| Q1 25 | — | $-129.6M | ||
| Q4 24 | — | $-59.2M | ||
| Q3 24 | — | $-85.7M |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | -169.0% | ||
| Q3 25 | 41.2% | -173.5% | ||
| Q2 25 | 35.4% | -269.8% | ||
| Q1 25 | — | -390.1% | ||
| Q4 24 | — | -919.0% | ||
| Q3 24 | — | -1314.3% |
| Q4 25 | — | -161.8% | ||
| Q3 25 | 31.7% | -209.8% | ||
| Q2 25 | 30.0% | -350.3% | ||
| Q1 25 | — | -784.9% | ||
| Q4 24 | — | -783.4% | ||
| Q3 24 | — | -1404.0% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $0.54 | $-0.07 | ||
| Q2 25 | $0.57 | $-0.10 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | — | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $250.4M | $-500.5M |
| Total Assets | $2.3B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | — | $257.8M | ||
| Q2 25 | — | $153.7M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $130.4M |
| Q4 25 | — | $-500.5M | ||
| Q3 25 | $250.4M | $-524.3M | ||
| Q2 25 | $209.4M | $-570.7M | ||
| Q1 25 | — | $-591.4M | ||
| Q4 24 | — | $-489.1M | ||
| Q3 24 | — | $-745.1M |
| Q4 25 | — | $501.9M | ||
| Q3 25 | $2.3B | $519.0M | ||
| Q2 25 | $2.2B | $402.1M | ||
| Q1 25 | — | $303.8M | ||
| Q4 24 | — | $382.9M | ||
| Q3 24 | — | $364.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.5M | $-70.4M |
| Free Cash FlowOCF − Capex | $-5.9M | $-71.3M |
| FCF MarginFCF / Revenue | -27.7% | -186.2% |
| Capex IntensityCapex / Revenue | 1.9% | 2.4% |
| Cash ConversionOCF / Net Profit | -0.82× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-70.4M | ||
| Q3 25 | $-5.5M | $-68.9M | ||
| Q2 25 | $-16.8M | $-79.7M | ||
| Q1 25 | — | $-85.9M | ||
| Q4 24 | — | $-85.1M | ||
| Q3 24 | — | $-98.8M |
| Q4 25 | — | $-71.3M | ||
| Q3 25 | $-5.9M | $-69.6M | ||
| Q2 25 | $-17.9M | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | — | $-87.3M | ||
| Q3 24 | — | $-101.6M |
| Q4 25 | — | -186.2% | ||
| Q3 25 | -27.7% | -217.2% | ||
| Q2 25 | -90.3% | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | — | -1155.4% | ||
| Q3 24 | — | -1663.2% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 1.9% | 2.3% | ||
| Q2 25 | 5.5% | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 45.7% |
| Q4 25 | — | — | ||
| Q3 25 | -0.82× | — | ||
| Q2 25 | -2.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
